From Barchart: 2025-02-05 08:38:00

Amgen Inc. reported strong Q4 earnings with revenue reaching $9.1 billion, up 11% from last year, and adjusted EPS at $5.31, beating expectations. However, a cautious profit forecast for 2025 caused shares to drop over 1% in pre-market trading. The company’s full-year revenue for 2024 grew 19% to $33.4 billion.

Despite strong sales and revenue growth, Amgen’s 2025 guidance fell short of expectations, with projected earnings per share of $20.00 to $21.20, below analysts’ $20.82 estimate. Full-year revenue is forecasted at $34.3 billion, slightly missing the consensus of $34.53 billion. Investors are concerned about the company’s ability to maintain growth momentum.

Amgen’s impressive quarterly performance was overshadowed by concerns about its ability to sustain growth in the face of market pressures and pricing challenges. With strong product sales driving revenue growth in 2024, the company’s performance in the coming quarters will be crucial in determining its future growth trajectory.



Read more at Barchart:: Amgen Beats Q4 Estimates, But Weak 2025 Outlook We…